We have launched a board of Reviewer Editors - click this link to apply.
Our hope is that will give public credit for the reviewing work many of you are doing already. If you have any questions before you apply, please get in touch.
This special issue of the Annals of Clinical Microbiology and Antimicrobials will focus on infections in immunocompromised populations, and we welcome submissions relating to clinical presentations, antimicrobial therapy, epidemiology, pathogen diagnostics and host immunology including host-pathogen interaction.
Guest Editor - Dr David Lowe (University College London)
Annals of Clinical Microbiology and Antimicrobials considers good quality, novel and international articles of more than regional relevance; the journal covers the clinical microbiology of bacteria, viruses and fungi, as well as antimicrobial treatment of infectious diseases in clinical settings.
Research articles must include epidemiological and/or clinical information about isolates; we also welcome systemic reviews, and clinical case reports of high international significance.
We often invite reviews focussing on important current issues, and we also welcome submission of formal systematic reviews. Authors who are considering submit an unsolicited review should contact the editorial office for advice on the relevance of the content and the quality of evidence that is expected.
Amanda is driven by the desire to make a difference in the world for the better, and her research has mainly been focused on the development of new diagnostics and drug discovery. She gained her PhD from the University of Nottingham (2002) in Molecular Biology and Biochemistry and her thesis work described the identification of a point mutation responsible for herbicide resistance in a grass week. She post-doc’ed at UCL (2001-2003) and Queen Mary, University of London, and it was during this second post-doc that she started working on the causative agent of human tuberculosis, Mycobacterium tuberculosis (Mtb) identifying new drug targets based and ended staying for 9 years. After a year in Sydney, Australia (2011-2012), Amanda joined Oxford Gene Technology where she led a team developing an NGS protocol to allow for the direct sequencing of pathogens from clinical specimens, including Mtb from sputum. In 2014 Amanda took a position at Cornell University, where she led a team screening over 1.2 million compounds for activity against Mtb in a macrophage model, and also developed a new cell-based screening assay – the deconstructed granuloma. Amanda joined Texas A&M in Feb 2020 as an assistant research professor, where her lab was focused on the development of new molecular based diagnostic assays, to be introduced to the Texas Veterinary Medical Diagnosis Laboratory (TVMDL). Since July 2021 Amanda has been working at Invitae in San Francisco, where she leads the lab-based efforts of the ID team, under the Metagenomics Arc.
Hakan Leblebicioglu, Editor-in-Chief
Professor Leblebicioglu is the former head of the Department of Infectious Diseases and Clinical Microbiology at Ondokuz Mayis University Medical School in Turkey and working at Samsun Liv Hospital, Turkey. He is currently a Fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), a founding member and Honorary Chief of ESCMID Study Group for Infections in Travelers and Migrants (ESGITM) and also a member of the Study Group for Viral Hepatitis (ESGVH). He has authored 162 publications in peer-reviewed international medical journals (H index is 31 in Web of Science), mainly in Crimean Congo hemorrhagic fever, viral hepatitis and healthcare associated infections. He has conducted workshops and courses in the area of effective communication, presentation skills, proposal and manuscript writing.
Tim McHugh, Editor-in-Chief
Professor McHugh leads the UCL Centre for Clinical Microbiology (CCM). Located at the Royal Free Hospital, CCM aims to improve the diagnosis and treatment of infectious diseases and contributes in the areas of antimicrobial resistance, infection in patients with immunosuppression and hospital acquired infection. Prof McHugh has a particular focus on respiratory infection and CCM has activities in all stages of the TB drug development pathway with projects on evaluation of new compounds as well as supporting the laboratory aspects of clinical trials. An underlying theme is the development of biomarkers of treatment outcome, whether transcriptomic analysis of in vitro treatments or the more complex picture of monitoring outcome in patients.
31 days to first decision for all manuscripts
86 days to first decision for reviewed manuscripts only
140 days from submission to acceptance
12 days from acceptance to publication
698,789 Downloads (2021)
499 Altmetric Mentions